奥昔托隆毒性的新证据
该研究为2002年1月至2016年5月间报告至昂热中毒与毒物警戒中心的奥昔托隆暴露病例的回顾性观察研究,共纳入43例,其中31例为自杀未遂。假定摄入剂量(60-3600 mg)与严重程度相关(rs=0.45,p=0.01)。摄入超过600 mg(中位剂量1200 mg)后观察到中等严重症状(嗜睡、肌张力增高、瞳孔缩小、惊厥、动脉低血压、QRS增宽、QTc延长),从1800 mg(中位剂量2700 mg)起观察到严重症状(昏迷、惊厥、QTc延长、QRS增宽、室性心动过速、动脉低血压、心源性休克)。4例在摄入后10-48小时出现症状二次加重。4例测定了血浆奥昔托隆浓度,浓度超过0.3 mg/L时观察到严重症状,2例最高血清奥昔托隆水平在摄入后20-48小时延迟出现。
要点
- 假定摄入剂量与严重程度相关(rs=0.45,p=0.01),摄入超过600 mg(中位1200 mg)可出现中等严重症状(PSS 2)。
- 摄入从1800 mg起(中位2700 mg)可观察到严重症状(PSS 3),包括昏迷、惊厥、QTc延长、QRS增宽、室性心动过速、动脉低血压、心源性休克。
- 4例在摄入后10-48小时出现症状二次加重。
- 4例测定了血浆奥昔托隆,浓度超过0.3 mg/L时观察到严重症状。
- 2例最高血清奥昔托隆水平在摄入后20-48小时延迟出现。
适用人群与场景
- 报告至昂热中毒与毒物警戒中心的奥昔托隆暴露病例,纳入43例,其中31例为自杀未遂。
- 排除数据不完整、奥昔托隆被认为不承担责任、临床症状主要与共同摄入药物相关或血浆奥昔托隆浓度阴性的病例。
诊断标准与关键阈值
- 严重程度采用中毒严重度评分(PSS)评估:PSS 2为中等严重症状(嗜睡、肌张力增高、瞳孔缩小、惊厥、动脉低血压、QRS增宽、QTc延长),PSS 3为严重症状(昏迷、惊厥、QTc延长、QRS增宽、室性心动过速、动脉低血压、心源性休克)。
红旗征与不能漏的情况
- 摄入超过600 mg(中位剂量1200 mg)后出现中等严重症状(PSS 2):嗜睡、肌张力增高、瞳孔缩小、惊厥、动脉低血压、QRS增宽、QTc延长。
- 摄入从1800 mg起(中位剂量2700 mg)出现严重症状(PSS 3):昏迷、惊厥、QTc延长、QRS增宽、室性心动过速、动脉低血压、心源性休克。
- 4例在摄入后10-48小时观察到症状二次加重。
- 血浆奥昔托隆浓度超过0.3 mg/L时观察到严重症状。
- 2例最高血清奥昔托隆水平在摄入后20-48小时延迟出现。
研究设计与关键结果
- 研究类型:回顾性观察研究;样本量:43例暴露病例,其中31例为自杀未遂;研究地点:昂热中毒与毒物警戒中心;时间范围:2002年1月至2016年5月。
- 假定摄入剂量(60-3600 mg)与严重程度相关(rs=0.45,p=0.01)。
- 摄入超过600 mg(中位剂量1200 mg)后观察到中等严重症状(PSS 2)。
- 摄入从1800 mg起(中位剂量2700 mg)观察到严重症状(PSS 3)。
- 4例在摄入后10-48小时出现症状二次加重。
- 4例测定了血浆奥昔托隆浓度,浓度超过0.3 mg/L时观察到严重症状;2例最高血清奥昔托隆水平在摄入后20-48小时延迟出现。
证据类型、等级与局限
- 证据类型:回顾性观察研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,若干临床和旁实验室参数强烈指向该分子的膜稳定特性以及症状延迟出现或二次加重的风险。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
CONTEXT: Oxetorone is a serotonin antagonist antimigraine drug but literature relating to its toxic properties is poor. The aim of this study is to describe the toxicological profile of oxetorone and to highlight any relationship between clinical and analytical findings.
MATERIALS AND METHODS: This is a retrospective and observational study of cases exposure to oxetorone, reported to the Angers Poison and Toxicovigilance Centre between January 2002 and May 2016. Severity was assessed using the Poisoning Severity Score (PSS). Cases where data were incomplete, where oxetorone was deemed not accountable, where clinical signs were linked mainly to a co-ingested drug or where the plasma concentration of oxetorone was negative were all excluded.
RESULTS: We included 43 cases of exposure, 31 of whom were suicide attempts. The assumed ingested dose (60-3600 mg) was correlated to severity (rs = 0.45, p = 0.01). Symptoms of moderate severity (PSS2 = drowsiness, hypertonia, myosis, convulsions, arterial hypotension, QRS widening, QTc prolongation) were observed following ingestion of more than 600 mg of oxetorone (median dose =1200 mg) and severe symptoms (PSS 3 = coma, convulsions, QTc prolongation, QRS widening, ventricular tachycardia, arterial hypotension, cardiogenic shock) were observed starting from 1800 mg (median dose =2700 mg). In four cases, a secondary worsening of symptoms 10-48 h following ingestion was observed. Plasma oxetorone was measured in four patients. Severe symptoms were observed in the event of a concentration over 0.3 mg/L and the highest measured serum oxetorone level was delayed by 20-48 h following the ingestion for two cases.
CONCLUSIONS: Several clinical and paraclinical parameters strongly point towards membrane-stabilising properties of the molecule and the risk of a delayed occurrence of symptoms or a secondary worsening.
参考来源
- Deguigne M, Bruneau C, Touré A, et al. New evidence for oxetorone toxicity. Clin Toxicol (Phila). 2016. PMID: 27967233. doi:10.1080/15563650.2016.1267358
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。